Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Kathleen M. Dungan MD, MPH Advisory Board

Deborah J. Wexler MD, MSc Associate Editor

See All Experts

featured

Published in Diabetes and

Journal Scan / Research · February 07, 2024

Glucagon Secretion and Its Association With Glycaemic Control and Ketogenesis During SGLT2 Inhibition by Ipragliflozin in People With Type 1 Diabetes

Diabetes, Obesity & Metabolism

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Carolina Gonzalez-Lopez MD

David Mathiesen MD

Casper Nielsen MSc, PhD

Diabetes, Obesity & Metabolism

Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study

Diabetes Obes Metab 2024 Jan 22;[EPub Ahead of Print], Y Nakamura, I Horie, T Kitamura, Y Kusunoki, K Nishida, A Yamamoto, Y Hirota, T Fukui, Y Maeda, M Minami, T Matsui, A Kawakami, N Abiru

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Obesity, Metabolic Syndrome, and Prediabetes

Glucagon Secretion and Its Association With Glycaemic Control and Ketogenesis During SGLT2 Inhibition by Ipragliflozin in People With Type 1 Diabetes

Additional Info

Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study

Further Reading

Technology in Managing Diabetes in Hospitalised Adults

Replication of the European Subtypes of Type 2 Diabetes in a Chinese Population

Impact of GLP-1 Receptor Agonist–Based Treatments on Fat-Free Mass

Diabetes Technology in People With Diabetes and Advanced Chronic Kidney Disease

Effects of GLP-1 Receptor Agonists Used as an Adjunct to Insulin Therapy on HbA1c Levels and CGM Metrics in Adults With Type 1 Diabetes

Estimating the Risk of Consequences Following Hypoglycaemia Exposure

Implications of Continuous Ketone Monitoring in Clinical Practice

Impact of Automated Insulin Delivery System Use on Glycemic Control in Children and Adolescents With Type 1 Diabetes

Clinical Practice Guidelines for Managing Pregnancy Following Metabolic Bariatric Surgery

CGM-Based Metrics and Duration of Hypoglycaemic Events With Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine U100 in Insulin-Naive Type 2 Diabetes

Higher Fibre and Lower Carbohydrate Intake Are Associated With Favourable CGM Metrics in Type 1 Diabetes

Recently Updated